Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip

Status Terminated

Clinical Trial Summary

Previous studies have shown an increase in the concentration of mesenchymal stem cells (MSC's) in the setting of osteoarthritis of the knee and its correlation to severity. Researchers have shown that as there is an increase in the severity of the disease, the concentration of stem cells also increases. The purpose of this study is to determine if there is the same increase in stem cell concentration in patients with osteonecrosis (ON) of the femoral head.

Clinical Trial Description

Since the treatment of osteonecrosis is related to the severity of disease, namely articular cartilage collapse, the purpose of this study is to determine if the MSC concentration in synovial fluid can be correlated to disease stage. In order to do this the investigators will: Milestone #1: Determine the concentration of MSC's in the synovial fluid in patients with osteonecrosis. This work will be carried out utilizing FACS-based technique to synovial fluid stem cell sub-population. Milestone #2: Compare concentrations of MSC's in patients with pre collapse, post collapse osteonecrosis and "normal" hips. Patient-derived MSC will be quantified at the different stages of disease and assays will be performed in order to assess their viability. A control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement (FAI). Since FAI does not affect the intraarticular environment of the hip, theoretically these patients would have a "normal" concentration of synovial stem cells. ;

Study Design

Related Conditions & MeSH terms

Osteonecrosis

Clinical Trial Details

NCT number	NCT02941666
Study type	Observational
Source	Mayo Clinic
Contact
Status	Terminated
Phase
Start date	September 2016
Completion date	May 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04072055` - MOTO Post-marketing Surveillance Study
Terminated	`NCT01763684` - Oxford Signature vs. Conventional Global Study	N/A
Completed	`NCT00505219` - Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head	Phase 3
Withdrawn	`NCT02632903` - Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study	Phase 2
Active, not recruiting	`NCT01458782` - ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee	N/A
Completed	`NCT01583465` - Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty	N/A
Active, not recruiting	`NCT04401267` - Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma	Phase 2
Completed	`NCT03197623` - Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids	Phase 1
Active, not recruiting	`NCT05283148` - Sickle Cell Disease (SCD) Bone Pain Study	N/A
Completed	`NCT05684588` - Post-COVID-19 Sequelae: Osteonecrosis of Femoral Head	N/A
Terminated	`NCT03269409` - Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis	Phase 1
Completed	`NCT00913679` - A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty	N/A
Enrolling by invitation	`NCT02893293` - Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI	Phase 4
Completed	`NCT01345097` - A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients	Phase 4
Recruiting	`NCT00260897` - Molecular Genetic Study of Avascular Necrosis of the Femoral Head	N/A
Not yet recruiting	`NCT06016634` - Alendronate for Osteonecrosis in Adults With Sickle Cell Disease	Phase 2
Completed	`NCT02077647` - Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee
Recruiting	`NCT01619124` - Osteonecroses in Pediatric Patients With ALL	N/A
Completed	`NCT02458937` - Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis
Recruiting	`NCT02661139` - Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction